DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Donnelly H, Bernard EM, Rothkotter H, et al. Distribution of
pentamidine in patients with AIDS. J Infect Dis, 1988,
157:985–989.
Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease
inhibitor cures Chagas’ disease in an immunodeficientmouse
model of infection. Antimicrob Agents Chemother,
2007, 51:3932–3939.
Dunne RL, Dunn LA, Upcroft P, et al. Drug resistance in the
sexually transmitted protozoan Trichomonas vaginalis. Cell
Res, 2003, 13:239–249.
Favennec L, Jave-Ortiz J, Gargala G, et al. Double-blind, randomized,
placebo-controlled study of nitazoxanide in the treatment
of fascioliasis in adults and children from northern Peru.
Aliment Pharmacol Therm, 2003, 17:265–270.
Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment
for antiparasitic drug discovery. Trends Parasitol, 2007,
23:589–595.
Freeman CD, Klutman NE, Lamp KC. Metronidazole: A therapeutic
review and update. Drugs, 1997, 54:679–708.
Gal M, Brazier JS. Metronidazole resistance in Bacteroides
spp. carrying nim genes and the selection of slow-growing
metronidazole-resistant mutants. J Antimicrob Chemother,
2004, 54:109–116.
Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol
Rev, 2001, 14:114–128.
Grishin NV, Osterman AL, Brooks HB, et al. The X-ray structure
of ornithine decarboxylase from Trypanosoma brucei: The
native structure and the structure in complex with α-difluoromethylornithine.
Biochemistry, 1999, 38:15174–15184.
Gross U. Treatment of microsporidiosis including albendazole.
Parasitol Res, 2003, 90(suppl):14–18.
Hand IL, Wiznia AA, Porricolo M, et al. Aerosolized pentamidine
for prophylaxis of Pneumocystis carinii pneumonia in
infants with human immunodeficiency virus infection. Pediatr
Infect Dis J, 1994, 13:100–104.
Hewitt RG, Yiannoutsos CT, Higgs ES, et al. Paromomycin: No
more effective than placebo for treatment of cryptosporidiosis
in patients with advanced human immunodeficiency virus
infection. AIDS Clinical Trial Group. Clin Infect Dis, 2000,
31:1084–1092.
Hlavsa MC, Watson JC, Beach MJ. Giardiasis surveillance—
United States, 1998–2002. MMWR 2005, 54:9–16.
Hoffman PS, Sisson G, Croven MA, et al. Antiparasitc drug nitazoxanide
inhibits the pyruvate oxidoreductases of
Helicobacter pylori, selected anaerobic bacteria and parasites
and Campylobacter jejuni. Antimicrob Agents Chemother,
2007, 51:868–876.
Kennedy PG. The continuing problem of human African trypanosomiasis
(sleeping sickness). Ann Neurol, 2008, 64:116–126.
Lamp KC, Freeman CD, Klutman NE, Lacy MK.
Pharmacokinetics and pharmacodynamics of the nitroimidazole
antimicrobials. Clin Pharmacokinet, 1999, 36:353–373.
Land KM, Johnson PJ. Molecular mechanisms underlying
metronidazole resistance in trichomonads. Exp Parasitol,
1997, 87:305–308.
Lejon V, Boelaert M, Jannin J, et al. The challenge of
Trypanosoma brucei gambiense sleeping sickness diagnosis
outside of Africa. Lancet Infect Dis, 2003, 3:804–808.
Leoung SG, Feigal DW Jr, Montgomery AB, et al. Aerosolized
pentamidine for prophylaxis against Pneumocystis carinii
pneumonia: The San Francisco community prophylaxis trial.
N Engl J Med, 1990, 323:769–775.
Maina N, Maina KJ, Maser P, Brun R. Genotypic and phenotypic
characterization of Trypanosoma brucei gambiense isolates
from Ibba, South Sudan, an area of high melarsoprol
treatment failure rate. Acta Trop, 2007, 104:84–90.
Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and
design of a randomized placebo-controlled trial assessing the
effects of etiologic treatment in Chagas’ cardiomyopathy: the
BENznidazole Evaluation For Interrupting Trypanosomiasis
(BENEFIT). Am Heart J, 2008, 156:37–43.
McFarland LV. Renewed interest in a difficult disease: Clostridium
difficile infections—epidemiology and current treatment strategies.
Curr Opin Gastroenterol, 2008, 25:24–35.
McGeary RP, Bennett AJ, Tran QB, et al. Suramin: Clinical uses
and structure-activity relationships. Mini Rev Med Chem,
2008, 8:1384–1394.
Mdachi RE, Thuita JK, Kagira JM, et al. Efficacy of the novel
diamidine compound 2, 5-bis (4-amidinophenyl)-furan-bis-Omethylamidoxime
(pafuramidine, DB289) against T. b. rhodesiense
infection in vervet monkeys after oral administration.
Antimicrob Agents Chemother, 2009, 53:953–957.
Medecins Sans Frontieres. Clinical guidelines, 2007; available
at: www.refbooks.msf.org/msf_docs/en/clinical_guide/CG_en.
pdf; accessed June 2, 2010.
Medical Letter. Drugs for parasitic infections. Met Lett Drugs
Ther, 2007, 5:e1–e15.
Mendz GL, Mégraud F. Is the molecular basis of metronidazole
resistance in microaerophilic organisms understood? Trends
Microbiol, 2002, 10:370–375.
Meyerhoff A. U.S. Food and Drug Administration approval of
AmBicome (liposomal amphotericin B) for the treatment of
visceral leishmaniasis. Clin Infect Dis, 1999, 28:42–48.
Milord F, Loko L, Éthier L, et al. Eflornithine concentrations in
serum and cerebrospinal fluid of 63 patients treated for
Trypanosoma brucei gambiense sleeping sickness. Trans R
Soc Trop Med Hyg, 1993, 87:473–477.
Molina JM, Tourneur M, Sarfati C, et al. Fumagillin treatment of
intestinal microsporidiosis. N Engl J Med, 2002, 346:1963–1969.
Montoya JG, Liesenfield O. Toxoplasmosis. Lancet, 2004,
363:1965–1976.
Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular
meglumine antimoniate alone and in combination with
intralesional meglumine antimoniate in the treatment of old
world cutaneous leishmaniasis. Acta Dermatovenerol Croat,
2008, 16:60–64.
Mutomba MC, Li F, Gottesdiener KM, Wang CC. A
Trypanosoma brucei bloodstream form mutant deficient in
ornithine decarboxylase can protect against wild-type infection
in mice. Exp Parasitol, 1999, 91:176–184.
Nash TE. Treatment of giardia lamblia infections. Pediatr Infect
Dis J, 2001, 20:193–195.
Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical
trial of sodium stibogluconate (Pentostam) versus ketoconazole
for treating cutaneous leishmaniasis in Guatemala.
J Infect Dis, 1992, 165:528–534.
Nwaka S, Hudson A. Innovative lead discovery strategies for
tropical diseases. Nat Rev Drug Discov, 2006, 5:941–955.
Obaji J, Lee-Pack LR, Gutierrez C, Chan CK. The pulmonary
effects of long-term exposure to aerosol pentamidine: A 5-year
1439
CHAPTER 50
CHEMOTHERAPY OF PROTOZOAL INFECTIONS